Lack of cytoplasmic expression of a new marker programmed cell death ligand-1 in tumor cells is significant

Table 2 The severity of cytoplasmic programmed cell death protein 1 ligand 1 expression in tumor cells according to the clinical and pathological characteristics of breast cancer

Breast cancer characteristics	Severity of cPDCD1 LG1 expression in the tumor cells	Р value
T stage
Тin situ	8.0 ± 2.8	0.86
Т1в	8.4 ± 2.4
Т1с	8.5 ± 2.3
Т2	8.2 ± 2.2
N stage
N0	8.7 ± 2.2	0.67
N1	8.3 ± 1.9
N2	6.9 ± 2.5
N3	9.1 ± 3.3
Clinical stage
0	8.0 ± 2.8	0.906
I (IA)	8.7 ± 2.3
IIA	8.5 ± 1.9
IIB	8.1 ± 1.9
IIIA	6.8 ± 2.6
IIIB	9.1 ± 3.2
Tumor grade
G1	9.4 ± 2.2	0.003a
G2	8.6 ± 2.5
G3	7.6 ± 1.9
Lymphovascular invasion
Absent	8.6 ± 2.2	0.27
Present	8.1 ± 2.2
Perineural invasion
Absent	8.7 ± 2.2	0.12
Present	7.7 ± 2.3
Intraductal component
Absent	8.5 ± 2.1	0.44
Present	8.0 ± 2.4
Estrogen receptor status
Negative	8.3 ± 1.2	0.87
Positive	8.4 ± 2.3
Progesterone receptor status
Negative	7.4 ± 2.1	0.0009a
Positive	8.7 ± 2.2
HER2 status
HER2 -	8.7 ± 2.4	0.15
HER2 1+	8.1 ± 1.3
HER2 2+	7.4 ± 2.8
HER2 3+	8.1 ± 1.3
Breast cancer molecular biological subtype
Luminal A	8.3 ± 2.5	0.41
Luminal B HER2-	8.4 ± 2.2
Luminal B HER2+	8.8 ± 2.1
Nonluminal HER2+	8.3 ± 1.2
TNBC	8.5 ± 1.2

^aP < 0.05 was considered statistically significant.

Statistical tests: Mann-Whitney U test - for two groups; Median test - for three or more groups. TNBC: Triple negative breast cancer; HER2: Human epidermal growth factor receptor 2; cPDCD1 LG1: Cytoplasmic programmed cell death protein 1 ligand 1.